Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
Author:
Affiliation:
1. Stanford University Medical Center; Stanford CA USA
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12573/fullpdf
Reference43 articles.
1. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;Journal of Clinical Oncology,2013
2. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia;Amrein;Clinical Cancer Research,2011
3. Ibrutinib (PCI-32765), the first BTK (Bruton's Tyrosine Kinase) inhibitor in clinical trials;Brown;Current Hematologic Malignancy Reports,2012
4. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies;Brown;Leukemia and Lymphoma,2013
5. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL);Brown;Journal of Clinical Oncology,2012a
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08
2. Labeling of Bruton’s Tyrosine Kinase (BTK) Inhibitor [11C]BIO-2008846 in Three Different Positions and Measurement in NHP Using PET;International Journal of Molecular Sciences;2024-07-18
3. Covalent drug – An emerging framework for targeted drug development;Results in Chemistry;2024-06
4. Surface-associated antigen induces permeabilization of primary mouse B-cells and lysosome exocytosis facilitating antigen uptake and presentation to T-cells;ELIFE;2021
5. Surface-associated antigen induces permeabilization of primary mouse B-cells and lysosome exocytosis facilitating antigen uptake and presentation to T-cells;eLife;2021-10-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3